Telix Pharmaceuticals Ltd (TLX) shareholders
Close on Nov 17, 2026Market cap $3.00BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Behrenbruch Christian Joint filing with Elk River Holdings Pty Ltd (6.78%) | 23,329,006 | 6.97% | 13G (passive) | Nov 12, 2024 |
| Kluge Andreas Joint filing with Gnosis Verwaltungsgesellschaft m.b.H. (6.78%) | 22,675,000 | 6.78% | 13G (passive) | Nov 12, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 561,206 | – | $6.47M | −3,551 | 0.00% |
| Lazard Asset Management LLC | 284,207 | – | $3.28M | −5,710 | 0.00% |
| Portland Investment Counsel Inc. | 266,200 | – | $3.07M | – | 0.86% |
| Private Advisor Group, LLC | 197,250 | – | $2.27M | +22,835 | 0.01% |
| Marshall Wace, Llp | 189,188 | – | $2.18M | New | 0.00% |
| Morgan Stanley | 165,978 | – | $1.91M | +49,538 | 0.00% |
| Integrated Wealth Concepts LLC | 164,397 | – | $1.90M | – | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 150,138 | – | $1.73M | New | 0.05% |
| UBS Group AG | 134,698 | – | $1.55M | +102,398 | 0.00% |
| Blair William & Co/Il | 122,985 | – | $1.42M | New | 0.00% |
| Raiffeisen Bank International AG | 115,000 | – | $1.30M | −15,000 | 0.02% |
| Quadrature Capital Ltd | 102,425 | – | $1.18M | New | 0.01% |
| JPMorgan Chase & Co | 77,538 | – | $876.19K | +20,190 | 0.00% |
| XY Capital Ltd | 71,291 | – | $821.99K | +58,739 | 0.79% |
| XTX Topco Ltd | 68,776 | – | $792.99K | +42,769 | 0.01% |
| Vanguard Personalized Indexing Management, LLC | 58,989 | – | $680.14K | +25,736 | 0.01% |
| NLB Skladi, upravljanje premozenja, d.o.o. | 58,000 | – | $668.74K | New | 0.03% |
| Mariner, LLC | 37,085 | – | $427.59K | −6,361 | 0.00% |
| Capricorn Fund Managers Ltd | 36,100 | – | $416.23K | New | 0.03% |
| Gts Securities LLC | 35,537 | – | $409.74K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 3M | 24 / 21 | 8 / 1 | 1M | 1M |
| Q1 2026 | 39 | 3M | 10 / 17 | 8 / 11 | 2M | 0M |
| Q4 2025 | 40 | 1M | 17 / 11 | 9 / 4 | 1M | 0M |
| Q3 2025 | 27 | 1M | 13 / 8 | 4 / 7 | 1M | 0M |
| Q2 2025 | 21 | 0M | 16 / 3 | 2 / 1 | 0M | 0M |
| Q1 2025 | 6 | 0M | 5 / 0 | 1 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held TLX in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Strategic Advisers U.S. Total Stock Fund | 434,667 | – | $4.10M | 0.00% | May 31, 2026 |
| ActivePassive International Equity ETF | 8,097 | – | $76.35K | 0.01% | May 31, 2026 |
| River Oak Discovery Fund | 5,000 | – | $49.45K | 0.26% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,694 | – | $44.26K | 0.00% | May 31, 2026 |
| Steward Values Enhanced International Fund | 3,943 | – | $39.00K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Christian Behrenbruch | MD & Group CEO, Director | 20,996,941 | May 6, 2026 |
| Darren Charlton Smith | Group Chief Financial Officer | 13,992 | Sep 14, 2026 |
| David Norman Cade | Group Chief Medical Officer | 373,133 | Apr 1, 2026 |
| Darren Joel Patti | Group Chief Operating Officer | 25,558 | Apr 1, 2026 |
| David N. Gill | Director | – | May 18, 2026 |
| William R. Jellison | Director | – | May 18, 2026 |
| Maria Rivas | Director | – | May 18, 2026 |
| Mark Alexander Nelson | Director | 3,628,750 | Apr 1, 2026 |
| Jann Elizabeth Skinner | Director | 595,000 | Mar 18, 2026 |
| Marie Elizabeth McDonald | Director | 3,719 | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Darren Charlton Smith Group Chief Financial Officer | Sep 7, 2026 | Buy | +2,071 | $9.66 | $20.01K | 13,992 |
| Christian Behrenbruch MD & Group CEO, Director | Apr 29, 2026 | Buy | +33,435 | $14.87 | $497.18K | 20,742,935 |
| Christian Behrenbruch MD & Group CEO, Director | Apr 28, 2026 | Buy | +34,500 | $14.48 | $499.56K | 20,709,500 |
| Darren Charlton Smith Group Chief Financial Officer | Mar 29, 2026 | Option exercise | +1,111 | – | – | 11,921 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Telix Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,528 shares on Sep 22, 2026 over the last 90 days.
See a number that looks wrong?